Success Metrics

Clinical Success Rate
72.6%

Based on 159 completed trials

Completion Rate
73%(159/219)
Active Trials
143(32%)
Results Posted
97%(155 trials)
Terminated
60(14%)

Phase Distribution

Ph phase_2
198
45%
Ph not_applicable
13
3%
Ph phase_4
24
5%
Ph phase_1
105
24%
Ph phase_3
93
21%
Ph early_phase_1
6
1%

Phase Distribution

111

Early Stage

198

Mid Stage

117

Late Stage

Phase Distribution439 total trials
Early Phase 1First-in-human
6(1.4%)
Phase 1Safety & dosage
105(23.9%)
Phase 2Efficacy & side effects
198(45.1%)
Phase 3Large-scale testing
93(21.2%)
Phase 4Post-market surveillance
24(5.5%)
N/ANon-phased studies
13(3.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.4%

159 of 229 finished

Non-Completion Rate

30.6%

70 ended early

Currently Active

143

trials recruiting

Total Trials

442

all time

Status Distribution
Active(161)
Completed(159)
Terminated(70)
Other(52)

Detailed Status

Completed159
Recruiting79
Active, not recruiting64
Terminated60
unknown47
Not yet recruiting16

Development Timeline

Analytics

Development Status

Total Trials
442
Active
143
Success Rate
72.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.4%)
Phase 1105 (23.9%)
Phase 2198 (45.1%)
Phase 393 (21.2%)
Phase 424 (5.5%)
N/A13 (3.0%)

Trials by Status

active_not_recruiting6414%
completed15936%
suspended51%
withdrawn102%
unknown4711%
terminated6014%
not_yet_recruiting164%
enrolling_by_invitation20%
recruiting7918%

Recent Activity

Clinical Trials (442)

Showing 20 of 442 trialsScroll for more
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT04803201Phase 2

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
NCT03407144Phase 2

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active Not Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT04980222Phase 2

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Active Not Recruiting
NCT01414855Phase 2

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Completed
NCT06977711Phase 1

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
NCT06738368Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Suspended
NCT00092222Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active Not Recruiting
NCT05600686Phase 2

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Active Not Recruiting
NCT06045247Phase 2

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT07194044Phase 1

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06630091Phase 2

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Recruiting
NCT06091865Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Recruiting
NCT07634471Phase 2

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Recruiting
NCT06220032Phase 3

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Recruiting
NCT05645718Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
442